# Alumis

Type: Company (ALMS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/alumis
Canonical HTML page: https://getbiobrief.com/entity/alumis

## Recent coverage (1 stories)

### Nyxoah and Alumis Miss Q4 Earnings Estimates Amid Scaling R&D Costs
2026-03-20 01:55:28 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Medical technology firm Nyxoah and immunology specialist Alumis both reported quarterly earnings that fell short of analyst expectations by $0.04 per share. The misses reflect the high capital intensity of late-stage clinical development and the commercial infrastructure build-out required for upcoming product launches.
Full story: https://getbiobrief.com/story/nyxoah-alumis-earnings-miss-q4-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.